Culture of ascitic ovarian cancer cells as a clinically-relevant ex vivo model for the assessment of biological therapies

European Journal of Gynaecological Oncology

Volumn 19, Issue 2, 1998, Pages 113-119

  Metcalf, K S ^b   Selby, P J ^b   Trejdosiewicz, L K ^b   Southgate, J ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b NONE

Author keywords

Ascites; Biological therapy; Cell surface antigen; Cytokine; Interferon alfa; Ovarian carcinoma; Primary culture

Indexed keywords

ALPHA INTERFERON; CA 125 ANTIGEN; CYTOKINE; HLA A ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; HLA DR ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MEMBRANE ANTIGEN;

ADULT; AGED; ARTICLE; ASCITES; ASCITES FLUID; BIOLOGICAL THERAPY; CANCER CELL CULTURE; CELL SURFACE; CELL SUSPENSION; CLINICAL ARTICLE; CONTROLLED STUDY; CULTURE MEDIUM; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; OVARY CANCER; OVARY CELL; PATIENT SELECTION; PHENOTYPE;

AGED; AGED, 80 AND OVER; ASCITIC FLUID; BIOPSY, NEEDLE; CA-125 ANTIGEN; FEMALE; FLOW CYTOMETRY; HLA ANTIGENS; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; SENSITIVITY AND SPECIFICITY; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 0031891315     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Einhorn N., Cantell K., Einhorn S., Strander H.: "Human leukocyte Interferon therapy for advanced ovarian carcinoma". Am. J. Clin. Oncol., 1982, 5, 167.
2. Freedman R. S., Gutterman J. U., Wharton J. T, Rutledge F. N.: "Leukocyte Interferon (IFN alpha) in patients with epithelial ovarian carcinoma". J. Biol. Respons. Mod., 1983, 2, 133.
3. Abdulhay G., DiSaia P. J., Blessing J. A., Creasman W. T.: "Human lymphoblastoid interferon in the treatment of advanced epithelial ovarian malignancies: a gynecologic oncology group study". Am. J. Obstet. Gynecol., 1985, 152, 418.
4. Niloff J. M., Knapp R. C., Jones G., Schaetzl E. M. and Bast R. C.: "Recombinant leukocyte alfa interferon in advanced ovarian carcinoma". Cancer Treat. Rep., 1985, 69, 895.
5. Einhorn N., Ling P., Einhorn S., Strander H.: "A phase II study on escalating interferon doses in advanced ovarian carcinoma". Am. J. Clin Oncol., 1988, 11, 3.
6. Berek J. S., Hacker N. F., Lichtenstein A., Jung T., Spina C., Knox R. M., Brady J., Greene T., Ettinger L. M , Lagasse L. D., Bonnem E. M., Spiegel R. J., Ziegelboim J.: "Intraperitoneal recombinant alfa-interferon for 'salvage' immunotherapy in stage III epithelial ovarian cancer" A Gynecologic Oncology Group Study. Cancer Res., 1985, 45, 4447.
7. Willemse P. H. B., deVries E.G.E., Mulder N. H, Aalders J. G., Bouma J., Sleijfer D. T. H.: "Intraperitoneal human recombinant Interferon alpha-2b in minimal residual ovarian cancer". Eur. J. Clin. Oncol., 1990, 26, 353.
8. Bezwoda W R., Golombick T., Dnasy R., Keeping J. "Treatment of malignant ascites due to recurrent / refractory ovarian cancer: the use of interferon-alpha or interferon-alpha plus chemotherapy. In vivo and in vitro observations". Eur J. Cancer, 1991, 27, 1423.
9. Mandelli F., Awisati G., Amadori S., Boccadoro M., Gernone A., Lanta V. M., Marmont F., Petrucci M T., Vegna M. L., Dammaeco F., Pileri A.: "Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy". New Eng. J. Med., 1990, 322, 1430.
10. Vedantham S., Gamliel H., Golomb H. M.: "Mechanism of interferon action in hairy cell leukaemia: a model of effective cancer biotherapy". Cancer Res., 1992, 52, 1056.
11. Metcalf K. S., Selby P. J., Trejdosiewicz L. K., Southgate J.: "Interferon induced changes in human ovarian cancer cell lines". Int. J. Gyn. Cancer. In press.
12. Epstein L. B , Shen J T., Abele J. S., Reese C. C.: "Sensitivity of human ovarian carcinoma cells to interferon and other antitumour agents as assessed by an in vitro semisolid agar technique". Ann. N. Y. Acad. Sci , 1980, 350, 228.
13. Balkwill F. R., Ward B. G., Moodie E., Thomas A J., Tavernier J., Fiers W.: "Therapeutic potential of tumour necrosis factor alfa and gamma interferon in experimental human ovarian cancer". Cancer Res., 1987, 47, 4755.
14. Malik S. T., Griffin D. B., Fiers W., Balkwill F. R.: "Paradoxical effects of tumour necrosis factor in experimental ovarian cancer". Int. J. Cancer, 1989, 44, 918.
15. Southgate J., Kennedy W., Hutton K. A. R., Trejdosiewicz L. K.: "Expression and in vitro regulation of integrins by normal human urothelial cells" Cell Adhes. Commun., 1995, 3, 231.
16. Stanley A. J., Banks R. E., Southgate J., Selby P.: "The effect of cell density on the expression of adhesion molecules and modulation by cytokines". Cytometry, 1995, 21, 338.
17. Nathan C., Sporn M.: "Cytokines in context". J. Cell. Biol., 1991, 113, 981.
18. Wu Y. J., Parker L. M., Binder N. E , Beckett M. A., Sinard J. H., Griffiths C. T., Rheinwald J. G.: "The mesothelial keratins: a new family of cytoskeletal proteins identified in cultured mesothelial cells and nonkeratinizing epithelia". Cell., 1982, 31, 703.
19. Hirte H. W., Clarke D. A., Mazurka J., O'Connell G., Rushoven J.: "A rapid and simple method for the purification of tumour cells from ascitic fluid of ovarian carcinoma". Gynecol. Oncol., 1992, 44, 223.
20. Fowler W. C., Maddock M. B., Moore D. H., Haskill S.: "Significance of multiparameter flow cytometric analysis of ovarian cancer". Am. J. Obstet. Gynecol, 1988, 158, 838.
21. Sahni K., Tribukait B., Einhorn N.: "Comparative study of S-phase cells in ascites and pleural effusions in ovarian carcinoma using antibromodeoxyuridine monoclonal antibody and DNA flow cytometry". Acta Oncol., 1989, 28, 705.
22. Guadagni F., Schlom J., Johnston W. W., Szpak C. A., Goldstein D., Smalley R., Simpson J. F., Bordin E. C., Pestka S., Greiner J. W.: "Selective interferon induced enhancement of tumour associated antigens on a spectrum of freshly isolated human adenocarcinoma cells". J. Natl. Cancer Inst., 1989, 87, 502.